AbbVie is looking to expand its presence in chronic lymphocytic leukemia (CLL) with new data on the Genmab-partnered CD20xCD3-directed bispecific antibody Epkinly (epcoritamab-bysp) in patients with relapsed/refractory disease.
The drug makers presented data from the expansion cohort of the Phase Ib/II EPCORE-CLL-1 trial in an oral presentation at the American Society of Hematology
Key Takeaways
- AbbVie/Genmab presented encouraging Phase Ib/II data in CLL at ASH for their CD20xCD3-directed bispecific antibody, Epkinly.
- The drug could provide an option for patients in later lines of CLL therapy, whose development has lagged that of non-Hodgkin lymphomas, along with the possibility of moving into earlier lines and combinations with small molecule drugs
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?